



## Proposals for NORMAN Joint Programme of Activities 2024

<b>Title</b>	<b>Finetuning and testing the BioActivity DataBase (BADB)</b>
<b>Type of activity</b>	Research and database development
<b>Leader</b>	KWR
<b>Topic / activities</b>	<p><b>Background / Justification for the proposed activity:</b> When successful, the BADB will allow to compile the available experimental data for bioactivities of single substances and enable many different analyses of data obtained with in-vitro bioassays currently used in Europe.</p> <p><b>Description of the proposed activity and expected outcomes for 2024:</b> After the revision and upcoming data solicitation that was planned under JPA 2023, the BADB can, in the course of 2024, start to accommodate collected and uploaded data submitted by the collaborators that agreed to participate in this task. The main proposed activity for 2024 is to evaluate the quality of submitted data. A follow up with contributors will be done if there are misunderstandings/errors/missing information in the submitted data. A user test involving experts using the BADB will be organized, to find if the database is easy to navigate. If improvements are necessary, for either Data Collection Template or the user interface, this will be signaled and executed. A list of potencies of individual substances will be compiled/developed for each of the relevant Mode of Action (MoA; cooperation with WG2). A list of existing Effect-based Trigger Values (EBTs) will be compiled and completed for bioassays with enough data.</p> <p><b>Added value / Link with other NORMAN activities and / or other projects</b>  <ul style="list-style-type: none"> <li>- Future prioritization of substances in WP1 based on their potencies related to specific in-vitro toxicity endpoints</li> <li>- Selection of most sensitive bioassays based on MoA to detect prioritized substances (WG2)</li> <li>- Update of QSARs for toxicity predictions based on data from the BADB.</li> <li>- NORMAN JPA aiming to develop a physical link between the various NORMAN Database System modules (e.g., Bioassays database, EMPODAT monitoring data) will be pursued in 2025 with, for instance, the possibility to assess which substances could cause high bioassay effects in water samples. This is dependent on whether submitted data quantity and quality is sufficient to establish a meaningful link.</li> </ul> </p>
<b>Participants</b>	EI (Jaroslav Slobodnik), UBA (Peter von der Ohe), KWR (Miina Yanagihara, Tessa Pronk). Advisors: NIVA (Knut-Erik Tollefsen), UvA (Milo de Baat)
<b>Proposed in-kind contribution</b>	Testing and piloting functional uses of the BADB, reporting to NORMAN (all participants). Organizing a test by users (UBA, all participants).
<b>Contribution needed from NORMAN Association<sup>1</sup></b>	<p>The activities planned for the JPA 2023 (data solicitation (KWR, UBA) and adjusting the database structure and user interface (EI) will be completed in the beginning of 2024. These activities experienced a delay in 2023.</p> <p>Additional JPA Funds 2024 are requested for:</p> <ul style="list-style-type: none"> <li>• Outreach to data contributors and data evaluation, compilation of potencies of individual substances per MoA and EBTs (KWR, 3000 €).</li> <li>• Implementation and refinement of the BADB functionality and data upload (EI, 2000 €).</li> </ul> <p>Total amount 5,000 €</p>

<sup>1</sup> Please, provide here a transparent justification of the requested resources and of the in-kind contribution, thereby distinguishing between the costs associated with “person-months” for the organisation, the “travelling costs” for invited speakers and the costs for the logistics (e.g. meals, room rental etc.)